Breaks Categories: News

TuesdayFeb 07, 2023 1:20 pm

NetworkNewsBreaks – AERWINS Technology Inc. (NASDAQ: AWIN) Completes Business Combination with PONO Capital Corp.

AERWINS (NASDAQ: AWIN), the developer and manufacturer of air mobility platform, C.O.S.M.O.S. (Centralized Operating System for Managing Open Sky), and the XTURISMO Limited Edition Hoverbike, recently announced the closing of its business combination with Pono Capital Corp., a special purpose acquisition company, pursuant to the merger agreement between the parties. According to the update, the company closed the merger agreement with Pono Capital and its wholly owned subsidiary, Pono Merger Sub Inc., and AERWINS Inc., a Japanese company previously named AERWINS Technologies Inc. At the closing, Pono Merger Sub Inc. merged with and into AERWINS Inc., with AERWINS Inc. surviving…

Continue Reading

TuesdayFeb 07, 2023 12:19 pm

NetworkNewsBreaks – Utopia VR President Featured in Latest Episode of Bell2Bell Podcast

Utopia VR, one of the world’s first metaverse-as-a-service solutions for business, is featured in the most recent release from The Bell2Bell Podcast. During the interview, Utopia VR president Stuart Gray and Bell2Bell host Jonathan Keim discuss how the VR space has evolved and Utopia VR’s entry into the space. In addition, Gray provided a tour of one of Utopia VR’s 3D environments designed to help professionals collaborate and socialize. Gray also outlined the company’s business-focused strategy, explained how Utopia VR is integrating artificial intelligence (“AI”) into its platform and shared his vision for the future of the metaverse. The Bell2Bell…

Continue Reading

TuesdayFeb 07, 2023 12:14 pm

NetworkNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Receives Health Canada Regulatory Approval to Move Forward with Phase 1 Trial

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has received notification that it can move forward with its proposed phase 1 clinical trial in Canada. The notification came in the form of a No Objection Letter (“NOL”) from Health Canada. The letter gives FSD Pharma regulatory approval to proceed with its clinical trial of LUCID-21-302 (“Lucid-MS”), a novel drug candidate for the treatment of multiple sclerosis. The first-in-human clinical trial is designed to evaluate the safety…

Continue Reading

TuesdayFeb 07, 2023 12:03 pm

NetworkNewsBreaks – AppTech Payments Corp. (NASDAQ: APCX) Secures $5M in Registered Direct Offering, Concurrent Private Placement

AppTech (NASDAQ: APCX), an innovative fintech company powering seamless, omni-channel commerce between businesses and consumers, today announced the closing of its $5.0 million registered direct offering with a single institutional investor to sell 1,666,667 shares of its common stock and warrants to purchase up to 1,666,667 shares in a concurrent private placement. The combined purchase price for one share and one warrant was $3.00. AppTech secured approximately $5.0 million in aggregate gross proceeds, of which it intends to use the net proceeds and its existing cash for general corporate purposes. These include integrating Commerse(TM) platform clients, retiring all loan forbearance…

Continue Reading

TuesdayFeb 07, 2023 12:00 pm

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enrolls First Patient in Spain in Key Global Trial Studying Berubicin for Treatment of GBM

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that enrollment is continuing in its ongoing global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”). Specifically, the company is reporting that it has enrolled the first patient in Spain. As part of the trial, the company has opened 37 of 59 planned clinical trial sites; the sites are located in the United States, Italy, France, Spain and Switzerland. The company noted that it plans an interim analysis of the study when…

Continue Reading

TuesdayFeb 07, 2023 11:42 am

NetworkNewsBreaks – Nextech AR Solutions Corp. (CSE: NTAR) (OTCQX: NEXCF) (FSE: EP2) Achieves Major Breakthrough in 3D Model Texture Creation

Nextech (CSE: NTAR) (OTCQX: NEXCF) (FSE: EP2), an augmented reality (“AR”), metaverse company and 3D model supplier for Amazon and other leading ecommerce retailers and brands, today announced it has achieved, with the help of generative AI, a breakthrough in the field of texture expansion. According to the update, the company can now recreate high-quality 4K textures at scale from small 250px X 250px digital swatches in just seconds versus hours of manual labor. “Our technology shows over 720-fold improvement in speed,” said Nima Shashar, CTO of Nextech. “With this technology, we will revolutionize the 3D modeling industry and make…

Continue Reading

MondayFeb 06, 2023 3:46 pm

NetworkNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Robot Roadshow to Take the Spotlight in Vegas

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots, today announced that its Robot Roadshow will land at Silverton Hotel & Casino in Las Vegas, Nevada, from 10:00 a.m. to 2:00 p.m. PT on Feb. 7-9, 2023. The engaging experiential event is designed to grab attention, forge direct connections with potential clients, and strike up conversations in a compelling fashion. The announcement reads, “The Las Vegas Roadshow landing will be guided by Knightscope experts, and visitors will be able to interact directly with each of the ASRs and see the Knightscope Security Operations Center (‘KSOC’) user interface in action.…

Continue Reading

MondayFeb 06, 2023 3:33 pm

NetworkNewsBreaks – Sidus Space Inc. (NASDAQ: SIDU) Secures $5.2M in Underwritten Public Offering

Sidus Space (NASDAQ: SIDU), a “Space-as-a-Service” satellite company, recently announced the closing of its underwritten public offering of 17,250,000 shares of its Class A common stock (or pre-funded warrants in lieu thereof), which included the full exercise of the underwriters’ over-allotment option. Each share of Class A common stock was sold to the public at a price of $0.30. Sidus Space secured approximately $5.2 million in gross proceeds from the offering and intends to use the net proceeds for sales and marketing, operational costs, product development, manufacturing expansion and for working capital and other general corporate purposes. Boustead Securities LLC…

Continue Reading

MondayFeb 06, 2023 3:10 pm

NetworkNewsBreaks – Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) Grants RSUs as Part of Long-Term Incentive Plan

Eloro Resources (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec, recently announced that it has granted an aggregate of 300,000 restricted share units (the “RSUs”) to its senior officers pursuant to its long-term incentive plan. The company’s plan is designed to compensate and reward its directors, officers, consultants and employees for working towards Eloro’s long-term objectives in alignment with the shareholders’ best interests. All granted RSUs have performance-related milestones in connection with the advancement of the company’s Iska Iska silver-tin polymetallic project in…

Continue Reading

MondayFeb 06, 2023 2:01 pm

NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Animal Study Results Featured in Aegis Capital Corp. Updated Price Target

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is the subject of an updated report released from Aegis Capital Corp. The update reflects the strong results from BVXV’s latest animal study indicating that anti-COVID-19 NanoAb can prevent infection. According to the report, BiondVax reported that in a continuation of the study, COVID-19 illness was virtually prevented in hamsters that received BiondVax’s inhaled NanoAb and infected three hours later with SARS-CoV-2. The report noted that data gathered from the preclinical trial show that BiondVax’s…

Continue Reading